Significant efforts have been made to develop novel approaches to targeting CD248 for clinical cancer treatment, including the development of monoclonal antibodies, vaccines, radioimmunotherapy, antibody-drug conjugates (ADCs), and CAR-T. Here, CD248 is linked to cancer.